glp 1 drugs in development GLP-1 Receptor Agonist Market Size & Analysis, 2026-2033 GLP-1 Costs Explained: Managing Coverage

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises

revenue, with Ozempic alone accounting for half of the total

Step 2: Select Your Package Choose from available package options

The LEAN trial (Liraglutide Efficacy and Action in NASH) was a landmark study published in The Lancet (2016) demonstrating that liraglutide 1.8 mg daily led to NASH resolution in 39% of patients compared to 9% in the placebo group after 48 weeks

Drug therapy in obesity: a review of current and emerging treatments

Skinny-fat individuals are at risk for metabolic issues